259 related articles for article (PubMed ID: 9419352)
1. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage.
Chen L; Agrawal S; Zhou W; Zhang R; Chen J
Proc Natl Acad Sci U S A; 1998 Jan; 95(1):195-200. PubMed ID: 9419352
[TBL] [Abstract][Full Text] [Related]
2. MDM2 oncogene as a target for cancer therapy: An antisense approach.
Wang H; Zeng X; Oliver P; Le LP; Chen J; Chen L; Zhou W; Agrawal S; Zhang R
Int J Oncol; 1999 Oct; 15(4):653-60. PubMed ID: 10493945
[TBL] [Abstract][Full Text] [Related]
3. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
Wang H; Yu D; Agrawal S; Zhang R
Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
Wang H; Nan L; Yu D; Lindsey JR; Agrawal S; Zhang R
Mol Med; 2002 Apr; 8(4):185-99. PubMed ID: 12149568
[TBL] [Abstract][Full Text] [Related]
5. Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression.
Chen L; Lu W; Agrawal S; Zhou W; Zhang R; Chen J
Mol Med; 1999 Jan; 5(1):21-34. PubMed ID: 10072445
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis of tumoral and nontumoral lymphoid cells is induced by both mdm2 and p53 antisense oligodeoxynucleotides.
Capoulade C; Mir LM; Carlier K; Lécluse Y; Tétaud C; Mishal Z; Wiels J
Blood; 2001 Feb; 97(4):1043-9. PubMed ID: 11159535
[TBL] [Abstract][Full Text] [Related]
7. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation.
Higashiyama M; Doi O; Kodama K; Yokouchi H; Kasugai T; Ishiguro S; Takami K; Nakayama T; Nishisho I
Br J Cancer; 1997; 75(9):1302-8. PubMed ID: 9155050
[TBL] [Abstract][Full Text] [Related]
8. MDM2 oncogene as a novel target for human cancer therapy.
Zhang ; Wang H
Curr Pharm Des; 2000 Mar; 6(4):393-416. PubMed ID: 10788589
[TBL] [Abstract][Full Text] [Related]
9. Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models.
Zhang Z; Wang H; Prasad G; Li M; Yu D; Bonner JA; Agrawal S; Zhang R
Clin Cancer Res; 2004 Feb; 10(4):1263-73. PubMed ID: 14977824
[TBL] [Abstract][Full Text] [Related]
10. Mdm2 ligase dead mutants did not act in a dominant negative manner to re-activate p53, but promoted tumor cell growth.
Swaroop M; Sun Y
Anticancer Res; 2003; 23(4):3167-74. PubMed ID: 12926050
[TBL] [Abstract][Full Text] [Related]
11. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway.
Chen CY; Oliner JD; Zhan Q; Fornace AJ; Vogelstein B; Kastan MB
Proc Natl Acad Sci U S A; 1994 Mar; 91(7):2684-8. PubMed ID: 8146175
[TBL] [Abstract][Full Text] [Related]
12. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
Wang H; Nan L; Yu D; Agrawal S; Zhang R
Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
[TBL] [Abstract][Full Text] [Related]
13. Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop.
Arriola EL; Lopez AR; Chresta CM
Oncogene; 1999 Jan; 18(4):1081-91. PubMed ID: 10023685
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
Ghosh M; Huang K; Berberich SJ
Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
[TBL] [Abstract][Full Text] [Related]
15. The roles of E6-AP and MDM2 in p53 regulation in human papillomavirus-positive cervical cancer cells.
Traidej M; Chen L; Yu D; Agrawal S; Chen J
Antisense Nucleic Acid Drug Dev; 2000 Feb; 10(1):17-27. PubMed ID: 10726657
[TBL] [Abstract][Full Text] [Related]
16. Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53.
Blattner C; Sparks A; Lane D
Mol Cell Biol; 1999 May; 19(5):3704-13. PubMed ID: 10207094
[TBL] [Abstract][Full Text] [Related]
17. The mdm2 proto-oncogene.
Haines DS
Leuk Lymphoma; 1997 Jul; 26(3-4):227-38. PubMed ID: 9322885
[TBL] [Abstract][Full Text] [Related]
18. Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation.
Mu Z; Hachem P; Agrawal S; Pollack A
Prostate; 2004 Aug; 60(3):187-96. PubMed ID: 15176048
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells.
Capoulade C; Bressac-de Paillerets B; Lefrère I; Ronsin M; Feunteun J; Tursz T; Wiels J
Oncogene; 1998 Mar; 16(12):1603-10. PubMed ID: 9569028
[TBL] [Abstract][Full Text] [Related]
20. Suppression of the p300-dependent mdm2 negative-feedback loop induces the p53 apoptotic function.
Thomas A; White E
Genes Dev; 1998 Jul; 12(13):1975-85. PubMed ID: 9649502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]